Xenon Pharmaceuticals Inc.
Developing ion-channel modulators for epilepsy and neuropsychiatric disease, led by late-stage Kv7 opener azetukalner.
Neurology & neuropsychiatry · Ion-channel modulators · Phase 3 / NDA planned Q3 2026
Developing ion-channel modulators for epilepsy and neuropsychiatric disease, led by late-stage Kv7 opener azetukalner.
Neurology & neuropsychiatry · Ion-channel modulators · Phase 3 / NDA planned Q3 2026